Drug intelligence / Profile preview

SPVX06

Development stage: Preclinical
Lead developer: Stablepharma
Modality: Vaccines & Immunotherapeutics
Administration: Injection

Overview

SPVX06 is a fridge-free tetanus vaccine developed by Stablepharma using its StablevaX™ technology. This technology converts existing approved vaccines, such as the Tetanus Toxoid (TT) vaccine manufactured by Bulbio Ltd (BB-NCIPD), into thermostable, lyophilized single-dose vials that do not require cold-chain storage. This innovation aims to significantly expand global access to vaccines by reducing wastage and logistical challenges associated with temperature-controlled supply chains. In-vivo studies have shown that SPVX06 maintains its potency and effectively stimulates the immune system to produce antibodies, exceeding WHO requirements for tetanus vaccines.

Other names: Tetanus mono vaccinefridge-free Tetanus vaccineStablevaX™ tetanus vaccine

Beyond the preview

Go deeper on SPVX06.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPVX06.

Explore the full profile